Vinícius Molla

Hematologist

[Vinícius Molla @viniciusmolla]

Favorable outcomes of restrictive treatment indications in chronic lym... https://t.co/werHjHxAWI

[Vincent Rajkumar @VincentRK]

My Updated Myeloma Treatment Algorithms. #ASCO25
Bookmark!

Presented at COMy.

1) Newly Diagnosed myeloma transplant ineligible.

[Javier Bolaños Meade, MD @GvHD_Meade]

I am getting old... a decade ago #PTCy was an exotic recipe exclusively used by @hopkinskimmel and few other centres. Today at #Tandem24 there is no BMT presentation not using it! #PTCyRules #ChangingTheWorld

[Keith W Pratz MD @PratzKW]

Happy to share the LTFU data from VIALE-A Phase III trial for Newly diagnosed AML unfit for induction. With 43.2 months follow up median OS 14.7m with Venetoclax/Azacitidine. Details of dosing adjustments in patients on therapy >6 cycles included. https://t.co/wN89ZybVvB

[TMO EPM @EpmTmo]

*Spotify:* https://t.co/5bdW8bkYfn

*Youtube:* https://t.co/MrMTlBUo9b

*Apple Podcast:* https://t.co/Kv6sqjnOOx

*Google podcast:* https://t.co/tTU9IWYnAm

*Deezer:* https://t.co/XKF1Da9YGc

*Amazon Music:* https://t.co/PWOTdLRuFy

[TMO EPM @EpmTmo]

*Novo Episódio !*

Spotify: https://t.co/Om2oQRLk9n

Youtube: https://t.co/xTYF3L2EZl

Apple Podcast: https://t.co/Nsu9CbzYES

[Eddie Cliff @Eddie_Cliff]

Promising early outcomes with Spanish academic CAR T in non-Hodgkin lymphoma 👏 @BrJHaem

- 3 year PFS 40%, OS 52% 👀 (small numbers)
- ORR 73%, DOR 56% @ 3yr
- ⬆️LDH assoc worse PFS
- 4% Gr≥3 CRS, 2% Gr≥3 ICANS

https://t.co/It1A5XdsvM
@JulioDelgadoHem @Manel_JuanOtero

Access is key in CAR T!

[The Lancet Haematology @TheLancetHaem]

New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
https://t.co/74MH7fEAn6

[Toby Eyre @tobyeyre82]

#ASH23 abstracts out! Here is a highlight:
Check out this from the FLAIR @NCRI_partners trial
MRD-directed Rx length of Ibr+Ven vs FCR phase III RCT
Massive PFS adv + OS benefit for Ibr-Ven #CLL #lymsm
Congrats to all UK investigators, Tal M and Pete H.
https://t.co/PfXlhbcwZR

[Eddie Cliff @Eddie_Cliff]

Very nice table summarising upfront combination BTKi + BCL2i data in CLL
@NitinJainMD #iwCLL2023 #lymsm

[Mehdi Hamadani, MD @MediHumdani]

Fantastic summary BTKi CLL AE slide @TheIACH by @docawan

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

100% agree! This is an example of how trying to recommend a drug based on marginal data in an indication where other more promising drugs should be studied & could be better such as menin inhibitors

[Asad Naveed @dr_asadnaveed]

A literature review helps you build on existing knowledge, identify gaps and provide direction for future research.

Here is a list of simple tools you can use for your next literature review project.

Which one is your favorite?

[Talha Badar @TalhaBadarMD]

Brief summary of 2 pivotal trials. #leusm #AML #FLT3inhibitor

[Benlazar S M A @smbenlazar]

First-line MCL Treatment Recommendations in 2023

[Benlazar S M A @smbenlazar]

ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY #EHA23

[Benlazar S M A @smbenlazar]

PRESENTATION ID S229 PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA : A PHASE III RANDOMIZED, CONTROLLED STUDY #EHA23 #lymsm

[Kate Cwynarski @CwynKate]

Credit to #Seung-AhYahng& 🇰🇷 colleagues for #CNS Prophylaxis Randomised study👏
Reminder of delay #3 #R-CHOP if intercalate HD-MTX.
Any efficacy in either?
Having moved to discussing EOT HD-MTX in ‘high-risk’ pts recent data challenging that!
Moving to baseline imaging/CSF #EHA23

[Matt Dancho (Business Science) @mdancho84]

No matter how long I’ve been doing data science, I still get smacked in the face every once in a while.

True story. 🧵

#datascience #rstats